An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

This study is testing a new cell therapy called AcNK-Sup003 — a type of natural killer (NK) cell infusion — in patients with relapsed or treatment-resistant B-cell non-Hodgkin's lymphoma, a type of blood cancer. NK cells are immune cells that can naturally recognize and kill cancer cells, and this therapy uses specially prepared NK cells to boost that ability. **You may be eligible if...** - You are 18 or older with an expected survival of at least 3 months - Your lymphoma has been confirmed by biopsy and is CD20-positive and has relapsed or stopped responding to treatment - You have received at least two prior treatment regimens (including a CD20-targeting drug and an anthracycline chemotherapy) and your cancer has progressed or not responded - You are in reasonably good physical condition and your organs are functioning adequately - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have active central nervous system involvement of lymphoma - You have a serious heart condition, severe infection, or uncontrolled other cancer - You are pregnant or breastfeeding - You cannot use effective contraception Talk to your doctor to see if this trial is right for you.